Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-10
2010-10-05
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S287000, C546S200000, C548S518000
Reexamination Certificate
active
07807686
ABSTRACT:
The present invention relates to 2-(4-oxo4H-quinazolin-3-yl) acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
REFERENCES:
patent: 4438121 (1984-03-01), Obitz
patent: 6730695 (2004-05-01), Roux
patent: 7202267 (2007-04-01), Aulombard et al.
patent: WO 01/55130 (2001-08-01), None
patent: WO 2004/009585 (2004-01-01), None
patent: WO 2006/095014 (2006-09-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, p. 18.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.
Hackam, et al. JAMA, 296(14), 2006, 1731-1732.
International Search Report and Written Opinion dated Oct. 3, 2008 for related International Application No. PCT/US07/78022.
International Search Report and Written Opinion dated Oct. 7, 2008 for related International Application No. PCT/US07/77999.
Moss et al., “Catalytic cleavage of active phosphate and ester substrates by iodoso- and iodoxybenzoates,”J. Am. Chem. Soc. 106(9):2651-2655 (1984).
West, Anthony R., “Chapter 10. Solid Solutions”,Solid State Chemistry and Its Applications, pp. 358 and 365; John Wiley & Sons, Pub., New York (1988).
International Search Report and Written Opinion for PCT/EP2006/060612 issued Jun. 20, 2006.
Balawant et al., “Synthesis of Pratorimine,”Journal of Natural Product 49(1986) 445-448.
Bernardini et al., “In vivo and in vitro Effects of Arginine-Vasopressin Receptor Antagonists on the Hypothalamic-Pituitary-Adrenal Axis in the Rat,”Neuroendocrinology 60(1994) 503-508.
Borcherding et al., “Carbocyclic Nucleosides as Inhibitors of Human Tumor Necrosis Factor-α Production: Effects of the Stereoisomers of (3-Hydroxycyclopentyl)adenines,”J. Med. Chem. 39(1996) 2615-2620.
De Bold et al., “Arginine Vasopressin Potentiates Adrenocorticotropin Release Induced by Ovine Corticotropin-releasing Factor, ”J. Clin. Invest. 73(1984) 533-538.
De Goeij et al., “Repeated Stress-Induced Activation of Corticotropin-Releasing Factor Neurons Enhances vasopressin Stores and Colocalization with Corticotrophin-Releasing Factor in the Median Eminence of Rats,”Neuroendocrinology 53(1991) 150-159.
Freidinger et al., “Small Molecule Ligands for Oxytocin and Vasopressin Receptors,”Medicinal Research Reviews 17(1997) 1-16.
Holsboer et al., “Human Corticotropin-Releasing Hormone in Depression-Correlation with Thyrotropin Secretion following Thyrotropin-Releasing Hormone,”Biol. Psychiatry 21(1986) 601-611.
Plotsky et al., “Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats,”Mol. Brain Res. 18(1993) 195-200.
Rivier et al., “Modulation of stress-induced ACTH release by corticotrophin-releasing factor, catecholamines and vasopressin,”Nature 305(1983) 325-327.
Scott et al., “Vasopressin and the Regulation of Hypothalamic-Pituitary-Adrenal Axis Function: Implications for the Pathophysiology of Depression,”Life Sciences 62(1998) 1985-1988.
Sugimoto et al., “Molecular Cloning and Functional Expression of a cDNA Encoding the Human V1bVasopressin Recepto,”J. Biol. Chem. 269(1994) 27088-27092.
Venuti et al., “Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazo2[,1-b]lquinazoline,”J. Med. Chem. 31(1988) 2136-2145.
Chan Jui-Hsiang
Hoc Koc-Kan
Jokiel Patrick
Letourneau Jeffrey
Morphy John Richard
Hess Susan L.
N.V. Organon
Willis Douglas M
Wilson James O
LandOfFree
2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182519